In renal carcinoma and glioma, ETS1 promotes cell proliferation by up-regulating TGFα expression; in hepatocellular carcinoma, ETS1 promotes cell proliferation by activating the expressions of cyclin E and cyclin-dependent kinase 2 (CDK2) [22]. Here, CDK2 is linked to glioma.